In this issue:
Survival advantage with nivolumab in previously treated NSCLC
Predicting response to ICIs in EGFR-mutated NSCLC
Gefitinib ± pemetrexed + carboplatin in EGFR-mutated NSCLC
RRx-001 then platinum + etoposide in previously treated SCLC
LMWH: no survival advantage in a lung cancer trial
ECOG-ACRIN 5508: pemetrexed + bevacizumab maintenance therapy
Assessing biopsy sampling for predicting histology in diffuse MPM
Adding cediranib to platinumpemetrexed in unresectable MPM
Please login below to download this issue (PDF)